Jiangwei Li maintains a Buy rating on SPY, viewing the recent market pullback as a buying opportunity rather than the end of the bull market. Despite the Federal Reserve's rate hike to 3.75%-4.00%, historical data suggests rate increases do not necessarily reverse economic growth cycles or cause major stock declines. Li's macroeconomic model forecasts stable conditions through Q4 2026, supported by strong S&P 500 earnings growth projections of around 29% for Q3 and Q4, and 32.8% for the full year 2026. This outlook underpins his positive stance on the market despite recent volatility.
The SPY market outlook and rate hike context is provided here with Pluang platform data for reference. For readers following US stocks, here is Pluang's market snapshot as of Oct 19, 2026 19:41 WIB: of 150 priced US stocks tradable on Pluang, 77 rose and 70 fell today. Notable movers include FCEL at USD 13.55 (+4.23%), INTC at USD 93.57 (+4.14%), and AMAT at USD 426.00 (+4.08%).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
